Mostrar el registro sencillo del documento
Evaluación del efecto coadyuvante de 2H-cromen-2-ona para la prevención de convulsiones inducidas experimentalmente en ratones de laboratorio
dc.rights.license | Atribución-NoComercial-CompartirIgual 4.0 Internacional |
dc.contributor.advisor | Guerrero Pabon, Mario Francisco |
dc.contributor.author | Núñez Medina, Ángela Viviana |
dc.date.accessioned | 2023-08-08T17:57:23Z |
dc.date.available | 2023-08-08T17:57:23Z |
dc.date.issued | 2023 |
dc.identifier.uri | https://repositorio.unal.edu.co/handle/unal/84494 |
dc.description | ilustraciones, diagramas, fotografías |
dc.description.abstract | La epilepsia es una enfermedad potencialmente neurodegenerativa crónica que afecta a humanos y animales. La mayoría de los pacientes requieren la prescripción de fármacos antiepilépticos (FAE), no obstante, alrededor del 30% de ellos no presentan resolución completa de sus convulsiones, por lo que se categorizan como pacientes refractarios, es decir, individuos que a pesar de tener un régimen médico no tienen control de estas. Dicha condición hace que su calidad de vida se afecte. Por dicha particularidad de resistencia farmacológica, el objetivo de este trabajo fue evaluar el efecto como coadyuvante de cumarina (2H-cromen-2-ona) en la prevención de convulsiones. En este trabajo se evaluó la respuesta por parte de ratones de laboratorios en modelos de inducción de convulsión bajo los efectos de fármacos antiepilépticos como lo fueron carbamazepina, ácido valproico y levetiracetam, el uso de cumarina y la combinación de fármaco y cumarina, en estímulos de electroshock de alta intensidad (MES), modelo de baja frecuencia (6 Hz) e inducción química con pentilentetrazol (PTZ), adicionalmente se evaluó la neurotoxicidad aguda mediante la prueba de eje rodante (Rotarod). De la evaluación de cumarina (2H-cromen-2-ona), en primer lugar, en la prueba de eje rodante, se encontró que no hubo una alteración significativa en la motricidad de los individuos. En cuanto a los datos obtenidos en los ensayos de inducción de convulsión se pudo determinar que la combinación de carbamazepina y cumarina tuvo un potencial efecto anticonvulsivante en el modelo de MES, para los otros modelos se encontró una significancia menor con respecto al de MES. Los datos proporcionados en el documento sugieren que el uso en combinación de cumarina (2H-cromen-2-ona) con fármacos prototipo de primera línea en modelos de ratones, ejercería efectos anticonvulsivantes y un posible efecto sinérgico. (Texto tomado de la fuente) |
dc.description.abstract | Epilepsy is a potentially chronic neurodegenerative disease that affects humans and animals. The majority of patients require the prescription of antiepileptic drugs (AEDs). However, around 30% of them do not present complete resolution of their seizures, which is why they are categorized as refractory patients, that is, individuals who, despite having a medical regimen, have no control over these. This condition affects their quality of life. Due to this particularity of pharmacological resistance, the goal of this work was to evaluate the effect of coumarin (2H-chromen-2-one) as an adjuvant in the prevention of seizures. In this work, the response of laboratory mice in models of seizure induction under the effects of antiepileptic drugs such as carbamazepine, valproic acid, and levetiracetam, the use of coumarin and the combination of drug and coumarin, was evaluated in stimulation high-intensity electroshock (MES), low-frequency model (6 Hz), and chemical induction with pentylenetetrazol (PTZ), additionally acute neurotoxicity was evaluated using the rolling axis test (Rotarod). From the evaluation of coumarin (2H-chromen-2-one), first of all, in the rolling axis test, it was found that there was no significant alteration in the motor skills of the individuals. Regarding the data obtained in the seizure induction trials, it was possible to determine that the combination of carbamazepine and coumarin had a potential anticonvulsant effect in the MES model, lower significance was found at the other models concerning the MES model. The data provided in the document suggest that the use of coumarin (2H-chromen-2-one) in combination with first-line prototype drugs in mouse models would exert anticonvulsant effects and a possible synergistic effect. |
dc.format.extent | 108 páginas |
dc.format.mimetype | application/pdf |
dc.language.iso | spa |
dc.publisher | Universidad Nacional de Colombia |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ |
dc.subject.ddc | 610 - Medicina y salud |
dc.title | Evaluación del efecto coadyuvante de 2H-cromen-2-ona para la prevención de convulsiones inducidas experimentalmente en ratones de laboratorio |
dc.type | Trabajo de grado - Maestría |
dc.type.version | info:eu-repo/semantics/draft |
dc.publisher.program | Bogotá - Ciencias - Maestría en Ciencias - Farmacología |
dc.contributor.researchgroup | Grupo de Investigaciones en Farmacología Molecular (Farmol) |
dc.contributor.researchgroup | Grupo de Investigaciones en Farmacología Molecular (Farmol) |
dc.description.degreelevel | Maestría |
dc.description.degreename | Magister en Ciencias- Farmacología |
dc.description.researcharea | Farmacología experimental del sistema nervioso |
dc.description.researcharea | Farmacología Experimental del Sistema Nervioso |
dc.identifier.instname | Universidad Nacional de Colombia |
dc.identifier.reponame | Repositorio Institucional Universidad Nacional de Colombia |
dc.identifier.repourl | https://repositorio.unal.edu.co/ |
dc.publisher.faculty | Facultad de Ciencias |
dc.publisher.place | Bogotá, Colombia |
dc.publisher.branch | Universidad Nacional de Colombia - Sede Bogotá |
dc.relation.references | Abu-Aisheh MN, Al-Aboudi A., Mustafa MS, El-Abadelah MM, Ali SY, Ul-Haq Z, Mubarak MS. Coumarin Derivatives as Acetyl- and Butyrylcholinestrase Inhibitor: An in Vitro, Molecular Docking and Molecular. Estudio de Simulaciones Dinámicas. Heliyón. 2019; 5: e01552. doi: 10.1016/j.heliyon. 2019.e01552. |
dc.relation.references | Aghdash SN. Herbal Medicine in the Treatment of Epilepsy. Curr Drug Targets. 2021; 22(3):356-367. doi: 10.2174/1389450121999201001152221. |
dc.relation.references | Ainsworth C. Networking for new durgs. Nature Medicine. 2011; 17: 1166-1168. |
dc.relation.references | Annunziata F., Pinna C., Dallavalle S., Tamborini L., Pinto A. An Overview of Coumarin as a Versatile and Readily Accessible Scaffold with Broad-Ranging Biological Activities. Int. J. Mol. Sci. 2020; 21:4618. doi: 10.3390/ijms21134618. |
dc.relation.references | Apseloff G, Hilliard JB, Gerber N, Mays DC. Inhibition and induction of drug metabolism by psoralens: alterations in duration of sleep induced by hexobarbital and in clearance of caffeine and hexobarbital in mice. Xenobiotica. 1991; 21(11):1461-1471. |
dc.relation.references | Ariza S, Rincón J, Guerrero MF. Efectos sobre el sistema nervioso central del extracto etanólico y fracciones de Hygrophila tyttha Leonard. Rev.Col.Cienc. Quim.Farm. 2006; 35 (1): 106-119. |
dc.relation.references | Balamurugan E, Aggarwal M, Lamba A, Dang N, Tripathi M. Perceived trigger factors of seizures in persons with epilepsy. Seizure. 2013; 22(9): 743- 747. |
dc.relation.references | Bagetta G, Morrone LA, Rombolà L, Amantea D, Russo R, Berliocchi L, Sakurada S, Sakurada T, Rotiroti D, Corasaniti MT. Neuropharmacology of the essential oil of bergamota. Fitoterapia. 2010; 81: 453–461. |
dc.relation.references | Barton M, Klein B, Wolf H, White H.Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Research. 2001; 47(3): 217-227.doi.og/10.1016/S0920-1211(01)00302-3. |
dc.relation.references | Barreiro-Arcos ML, Cremaschi G, Werner S, Coussio J, Ferraro G, Anesini C.Tilia cordata Mill extracts and scopoletin (isolated compound): differential cell growth effects on lymphocytes. Phytother Res. 2006; 20(1):34-40. |
dc.relation.references | Berendt, M., Farquhar, R.G., Mandigers, P.J.J., Pakozdy, A., Bhatti, S.F.M., De Risio, L., Fischer, A., Long, S., Matiasek, K., Muñana, K., et al. International Veterinary Epilepsy Task Force consensus report on epilepsy definition, classification and terminology in companion animals. BMC Veterinary Research. 2015; 11, 182. |
dc.relation.references | Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, Engel J, French J, Glauser TA, Mathern GW, Moshé SL, Nordli D, Plouin P, Scheffer IE. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia. 2010 Apr;51(4):676-85. doi: 10.1111/j.1528-1167.2010.02522.x. |
dc.relation.references | Beyenburg S, Stavem K, Schmidt D. Placebo- corrected efficacy of modern antiepileptic drugs for refractary epilepsy: systematic review and meta-analysis. Neurology. 2010; 60: S13-S25. |
dc.relation.references | Bhat MA, Al-Omar MA. Coumarin incorporated triazoles: a new class of anticonvulsants. Acta Pol Pharm. 2011; 68(6):889-95. PMID: 22125954. |
dc.relation.references | Bilgin H, Atmaca M, Obaya B, Özekincib S, Ezel Taşdemirc E, Ketanid A. Protective effects of coumarin and coumarin derivatives against carbon tetrachloride-induced acute hepatotoxicity in rats. Exp Toxicol Pathol. 2011; 63(4):325-30. doi: 10.1016/j.etp.2010.02.006. Epub 2010 Mar 5. |
dc.relation.references | Bliss CI. The toxicity of poisons applied jointly. Annals of Applied Biology. 1939; 26(3): 585–615. DOI: DOI 10.1111/j.1744-7348. 1939.tb06990. x. |
dc.relation.references | Brodie MJ, Perucca E, Ryvlin P, Ben Menachem E, Meencke HJ. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007; 68: 402-408. |
dc.relation.references | Borges F, Roleira F, Milhanzes N, Santana L, Uriarte E. Simple coumarins and analogues in medicinal chemistry: Occurrence, synthesis and biological activity. Curr. Med. Chem. 2005; 12:887–916. doi: 10.2174/0929867053507315. |
dc.relation.references | Buntin K, Ertl P, Hoepfner D, Krastel P, Oakeley EJ, Pistorius D, Schuhmann T, Wong J, Petersen F. Deliberations on Natural Products and Future Directions in the Pharmaceutical Industry. Chimia (Aarau). 2021; 75(7):620-633. doi: 10.2533/chimia.2021.620. |
dc.relation.references | Carlton, B. D., Aubrun, J. C., and Simon, G. S. Effects of Coumarin Following Perinatal and Chronic Exposure in Sprague-Dawley Rats and CD-1 Mice. Fundam. Appl. Toxicol. 1996. 30 (1), 145–151. doi:10.1006/FAAT.1996.0051. |
dc.relation.references | Castagné V, Hernier A.M., Porsolt R.D. CNS Safety Pharmacology. Reference Module in Biomedical Sciences. Elsevier, 2014, https://doi.org/10.1016/B978-0-12-801238-3.04931-X. |
dc.relation.references | Castel-Branco, MM, Alves GL, Figueiredo IV, Falcão AC, Caramona MM. The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs. Methods Find Exp Clin Pharmacol. 2009; 31(2):101-106. doi: 10.1358/mf.2009.31.2.1338414. PMID: 19455265. |
dc.relation.references | Chattha FA, Munawar MA, Kousar S. Plant growth regulating activity of coumarin derivatives. Horticult In. 2018; tJ2: 24–29. |
dc.relation.references | Chaves ALP, Garzón NC, Cuca LE. Uso y manejo de la flora entre los Awa de Cuambi-Yaslambi, Barbacoas (Nariño, Colombia), Etnobotánica y Botánica económica. Bogotá: Universidad Nacional de Colombia; 2006. |
dc.relation.references | Chen G, Portman R, Ensor CR, Bratton AC Jr. The anticonvulsant activity of o-phenyl succinimides. J Pharmacol Exp Ther. 1951; 103:54–61. |
dc.relation.references | Diácono RM. Measuring motor coordination in mice. J Vis Exp. 2013;(75): e2609. doi: 10.3791/2609. PMID: 23748408; PMCID: PMC3724562. |
dc.relation.references | Detsi A., Kontogiorgis C., Hadjipavlou-Litina D. Coumarin Derivatives: An Updated Patent Review (2015–2016) Expert Opin. Ther. Pat. 2017; 27:1201–1226. doi: 10.1080/13543776.2017.1360284. |
dc.relation.references | Di Veroli GY, Fornari C, Wang D, Mollard S, Bramhall JL, Richards FM, Jodrell DI. Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics. 2016;32(18):2866-8. doi: 10.1093/bioinformatics/btw230. |
dc.relation.references | Eadie MJ. The use of antiepileptic drugs in clinical practice. In Eadie MJ, Vajda FJE (Eds) Antiepileptic drugs. Pharmacology and therapeutics, Springer, Berlin, 1999. pp. 589–614. |
dc.relation.references | Elger CE, Schmidt D. Manejo moderno de la epilepsia: un enfoque práctico. Epilepsia Comportamiento. 2008; 12: 501 – 539. |
dc.relation.references | Escobar, J. (2016). Estudio de la actividad anticonvulsivante de una pirazolo triazina obtenida por síntesis. Repositorio Universidad Nacional. Retrieved February 7, 2022, from https://repositorio.unal.edu.co/bitstream/handle/unal/58353/9737572.2016.pdf?sequence=1&isAllowed=y |
dc.relation.references | Felter SP, Vassallo JD, Carlton BD, Daston GP. A safety assessment of coumarin taking into account species-specificity of toxicokinetics. Food Chem Toxicol. 2006;44(4):462-75. doi: 10.1016/j.fct.2005.08.019. Epub 2005 Oct 3. PMID: 16203076. |
dc.relation.references | Fentem J, Fry J. (1993). Species differences in the metabolism and hepatotoxicity of coumarin. Comp. Biochem. Physiol. Part C. Vol.104, Issue 1:1-8. En: Martín-Aragón S. (1994). “Cumarinas en la prevención del estrés oxidativo dependiente de la edad”. Memoria para optar al título de Doctor en Farmacia. Universidad Complutense de Madrid, Facultad de Farmacia, Departamento de Farmacología. 202 p. |
dc.relation.references | Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger C, Forsgren L, French JA, Glynn M, Hesdorffer DC, Lee BI, Mathern GW, Moshé E, Scheffer IE, Tomson T, Watanabe M y Wiebe S. Definición clínica práctica de la epilepsia. Epilepsia. 2014; 55(4); 475-482. doi: 10.1111/epi.12550. |
dc.relation.references | Frearson J, Wyatt P Drug Discovery in Academia- the third way? Expert Opin. Drug Discov. 2010; 5(10):909-19. doi: 10.1517/17460441.2010.506508 |
dc.relation.references | Fonseca-Barriendos D, Frías-Soria CL, Pérez-Pérez D, Gómez-López R, Borroto Escuela DO, Rocha L. Drug-resistant epilepsy: Drug target hypothesis and beyond the receptors. Epilepsia Open. 2022 Aug;7 Suppl 1(Suppl 1):S23-S33. doi: 10.1002/epi4.12539. |
dc.relation.references | Germán, R., & Santiago, C. Epilepsia refractaria – Refractory epilepsy. Acta Neurológica Colombiana. Retrieved. 2022, from https://www.acnweb.org/acta/acta_2010_26_1-33-46.pdf |
dc.relation.references | Giardina, W. J. Models of Epilepsy: Electroshock and Chemical Induced Convulsions in the Mouse. Current Protocols in Pharmacology. 2001. doi:10.1002/0471141755.ph0522s10. |
dc.relation.references | Girón C, Ruiz L, Guerrero M. Implementación del modelo de convulsión con descargas eléctricas de baja frecuencia. 2009. Universidad Nacional de Colombia, Bogotá, Colombia. |
dc.relation.references | Goiz-Marquez, G., Caballero, S. Epilepsia en perros. Vet. Méx. 2008. 39 (3), 279- 321 from https://www.medigraphic.com/pdfs/vetmex/vm-2008/vm083e.pdf |
dc.relation.references | Golub V, Reddy DS Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders. Adv Exp Med Biol. 2021; 1264:93-110. doi: 10.1007/978-3-030-57369-0_7. |
dc.relation.references | Gorgus E, Lohr C, Raquet N, Guth S, Schrenk D. Limettin and furocoumarins in beverages containing citrus juices or extracts. Food Chem.Toxicol. 2010; 48: 93–98. |
dc.relation.references | Geary N. Understanding synergy. American Journal of Physiology-Endocrinology and Metabolism. 2013. 304(3): E237–E253. DOI: 10.1152/ajpendo.00308.2012. |
dc.relation.references | Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev. 1995 Jun; 47(2):331-85. PMID: 7568331. |
dc.relation.references | Greco WR, Faessel H, and Levasseur L. The search for cytotoxic synergy between anticancer agents: ¿a case of Dorothy and the ruby slippers? J Natl Cancer Inst. 1996; 88(11): 699–700. |
dc.relation.references | Harborne JB. Clases y funciones de los productos secundarios de las plantas En Sustancias químicas de las plantas: perspectivas sobre los productos secundarios de las plantas. Editado por Walton, NJ y Brown, Imperial College Press. 1999. págs. 1–25. |
dc.relation.references | Holbrook, A.M., Pereira, J.A., Labiris, R., McDonald, H., Douketis, J.D., Crowther, M., 2 Wells, P.S. Systematic overview of warfarin and its drug and food interactions. 3 Arch. Intern. Med. 2005; 165, 1095–1106. |
dc.relation.references | Hopkins, A. L. Network pharmacology: the next paradigm in drug Discovery. Nature Chemical Biology. 2008; 4, 682-690 |
dc.relation.references | Huang L, Yang S, Liou C, Hung P, Lai M, Wang C, Wang, T.Pentylenetetrazol-induced Recurrent Seizures in Rat Pups: Time Course on Spatial Learning and Long-term Effects. Epilep. 2002; 43 (6): 567-573. |
dc.relation.references | Illingworth JL, Watson P, Ring H. Why do seizures occur when they do? Situations perceived to be associated with increased or decreased seizure likelihood in people with epilepsy and intellectual disability. Epilepsy Behav. 2014; 39: 78- 84. |
dc.relation.references | IUPAC. Nomenclatura de Química Orgánica. Prensa de Pérgamo; Oxford, Reino Unido: 1979. |
dc.relation.references | Kang SY, Lee KY, Sung SH, Kim YC. Four new neuroprotective dihydropyranocoumarins from Angelica gigas. J Nat Prod. 2005; 68 (1):56-59. |
dc.relation.references | Kwan, P., Arzimanoglou, A., Berg, A., Brodie, M., Allen Hauser, W., & et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010; 51(6):1069–1077. |
dc.relation.references | Kohling R. Voltage - gated sodium channels in epilepsy. Epilepsia. 2002; 43: 1278 - 1295. |
dc.relation.references | Kumar AK, Renuka N, Pavithra G, Kumar GV Comprehensive review on coumarins: Molecules of potential chemical and pharmacological in- terest. J Chem Pharm Research. 2015. 7: 67–81. |
dc.relation.references | Kummerle AE, Vitorio F., Franco DP, Pereira TM Compuestos cumarínicos en química médica: algunos ejemplos importantes del último año. actual Cima. Medicina. química 2018; 18 :124–128. doi: 10.2174/1568026618666180329115523. |
dc.relation.references | Lamprea N, Guerrero M, Munevar A y Lamprea M. Interacción entre el extracto de Hygrophila tyttha y la escopolamina en una prueba de memoria episódica en ratas. Acta biol. Colomb. 2009; Vol. 14 No. 2, 41- 48. |
dc.relation.references | LAPA AJ, SOUCCAR C, LIMA MT, LIMA TCM. Métodos farmacológicos para el estudio de actividad sobre el sistema nervioso central. In: CYTED/ CNPq (Ed), Métodos de evaluación de la actividad farmacológica de plantas medicinales. 2002. pp 70:90. |
dc.relation.references | Lake, B. G., and Grasso, P. Comparison of the Hepatotoxicity of Coumarin in the Rat, Mouse, and Syrian Hamster: a Dose and Time Response Study. Fundam. Appl. Toxicol. 1996. 34 (1), 105–117. doi:10.1006/FAAT.1996.0181 |
dc.relation.references | Lubrich, C.; Giesler, P.; Kipp, M. Motor Behavioral Deficits in the Cuprizone Model: Validity of the Rotarod Test Paradigm. Int. J. Mol. Sci. 2022, 23, 11342. https://doi.org/10.3390/ijms231911342. |
dc.relation.references | Matos JM, Santana L, Uriarte E, Abreu OA, Molina E, Yordi EG Cou- marins – an important class of phytochemicals. In: Phytochemicals – Iso- lation, Characterization and Role in Human (Rao V, Rao LG, Ed.). In Tech, Rijeka. 2015; p. 113–140. |
dc.relation.references | Matovu D, Cavalheiro EA. Differences in Evolution of epileptic seizures and topographical distribution of tissue damage in selected libic structures between male and female rats submitted to pilocarpine model. Front. Neurol. 2022; 13:802587. doi: 10.3389/fneur.2022.802587 |
dc.relation.references | Mareš P., Kubová H., CHAPTER 12 - Electrical Stimulation-Induced Models of Seizures, Editor(s): Asla Pitkänen, Philip A. Schwartzkroin, Solomon L. Moshé,Models of Seizures and Epilepsy,Academic Press. 2006; Pages 153-159, https://doi.org/10.1016/B978-012088554-1/50014-1. |
dc.relation.references | Mohanraj R, Brodie MJ. Outcomes in newly diagnosed localization-related epilepsies. Seizure. 2005; 14:318–323. |
dc.relation.references | Muhammad, J., Khan, A., Ali, A., Fang L., Yanjing W., Xu Q and Wei DQ., Network pharmacology: Exploring the resources and methodologies. Current Topics in Medicinal Chemistry. 2018; 18;949-964. |
dc.relation.references | Muke S, Kaikini A, Peshattiwar V, Bagle S, Dighe V, Sathaye S. Neuroprotective Effect of Coumarin Nasal Formulation: Kindling Model Assessment of Epilepsy. Front Pharmacol. 2018; 9:992. doi: 10.3389/fphar.2018.00992. PMID: 30233371; PMCID: PMC6129593. |
dc.relation.references | Payá M, Halliwell B, Hoult JR. Interactions of a series of counmarins with reactive oxygen species. Scavenging of superoxide, hypochlorous acid and hydroxyl radicals. Biochem Pharmacol. 1992; 44 (2): 205-14. |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |
dc.subject.decs | Administración del Tratamiento Farmacológico |
dc.subject.decs | Medication Therapy Management |
dc.subject.decs | Epilepsia |
dc.subject.decs | Convulsiones |
dc.subject.decs | Seizures |
dc.subject.decs | Anticonvulsivantes |
dc.subject.decs | Anticonvulsants |
dc.subject.decs | EXPERIMENTACION CON ANIMALES |
dc.subject.decs | Animal experimentation |
dc.subject.decs | Epilepsy |
dc.subject.proposal | Epilepsia |
dc.subject.proposal | cumarina |
dc.subject.proposal | pentilentetrazol |
dc.subject.proposal | MES |
dc.subject.proposal | 6 Hz |
dc.subject.proposal | convulsión |
dc.subject.proposal | anticonvulsivo |
dc.subject.proposal | Epilepsy |
dc.subject.proposal | coumarin |
dc.subject.proposal | pentylenetetrazole |
dc.subject.proposal | seizure |
dc.subject.proposal | anticonvulsant |
dc.title.translated | Evaluation of the adjuvant effect of 2H-chromen-2-one for the prevention of experimentally induced seizures in laboratory mice |
dc.type.coarversion | http://purl.org/coar/version/c_b1a7d7d4d402bcce |
dc.type.content | Text |
oaire.accessrights | http://purl.org/coar/access_right/c_abf2 |
dcterms.audience.professionaldevelopment | Estudiantes |
dcterms.audience.professionaldevelopment | Investigadores |
dcterms.audience.professionaldevelopment | Maestros |
dcterms.audience.professionaldevelopment | Público general |
dc.contributor.cvlac | Angela Viviana Nuñez Medina [0001464046] |
Archivos en el documento
Este documento aparece en la(s) siguiente(s) colección(ones)
![Atribución-NoComercial-CompartirIgual 4.0 Internacional](/themes/Mirage2//images/creativecommons/cc-generic.png)